Filtered By:
Procedure: Hemodialysis
Vaccination: Influenza Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 30 results found since Jan 2013.
A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report
Int Immunopharmacol. 2023 Mar 2;117:109950. doi: 10.1016/j.intimp.2023.109950. Online ahead of print.ABSTRACTPURPOSE: Patients with end-stage renal disease (ESRD) on hemodialysis (HD) are considered particularly susceptible to infection with SARS-CoV2 on the basis of the immunodeficiency associated with advanced age, comorbidity burden, medication use, and need for frequent visits to dialysis clinics. In prior studies, thymalfasin (thymosin alpha 1, Ta1) has been shown to enhance antibody response to influenza vaccine and reduce influenza infection in geriatric populations, including hemodialysis patients, when used as an ...
Source: International Immunopharmacology - March 7, 2023 Category: Allergy & Immunology Authors: Cynthia W Tuthill Ahmed Awad Mary Parrigon William B Ershler Source Type: research
Egyptian hemodialysis patients' willingness to receive the COVID-19 vaccine booster dose: a multicenter survey
CONCLUSION: COVID-19 booster-dose hesitancy among HD patients in Egypt represents a major concern, is associated with vaccine hesitancy with respect to other vaccines and emphasizes the need to develop effective strategies to increase vaccine uptake.PMID:36862285 | PMC:PMC9979119 | DOI:10.1007/s40620-023-01586-z
Source: Journal of Nephrology - March 2, 2023 Category: Urology & Nephrology Authors: Hoda Mahmoud Mohammad Abdulaziz Marwa Ahmed Saleh Mohamed Essam Elrggal Mariam E Omar Shymaa A Hawash Ahmed Mohamed Naguib Attiya Karem Mohamed Salem Alaa Abdel-Aziz Sabry Source Type: research
Risks of central nervous system infections and related mortality in patients undergoing dialysis
CONCLUSIONS: The risks of CNS infections and related mortality were remarkably high in dialysis patients with no significant difference between patients with ESRD under HD and PD treatment.PMID:35107185 | DOI:10.1111/sdi.13058
Source: Seminars in Dialysis - February 2, 2022 Category: Urology & Nephrology Authors: Chueh-Hsuan Hsu Chueh-Lin Hsu Yu-Neng Shiu Po-Chang Lin Hung-Yu Huang Shih-Yi Lin Cheng-Li Lin Tung-Min Yu Tzung-Hai Yen Chi-Yuan Li I-Kuan Wang Source Type: research
End-Stage Renal Disease: Medical Management
Am Fam Physician. 2021 Nov 1;104(5):493-499.ABSTRACTEnd-stage renal disease (ESRD) is diagnosed when kidney function is no longer adequate for long-term survival without kidney transplantation or dialysis. Primary care clinicians should refer people at risk of ESRD to nephrology to optimize disease management. Kidney transplantation typically yields the best patient outcomes, although most patients are treated with dialysis. The decision to initiate dialysis is best made through shared decision-making. Because most patients with ESRD elect to receive hemodialysis, the preservation of peripheral veins is important for those...
Source: American Family Physician - November 16, 2021 Category: Primary Care Authors: Noah Wouk Source Type: research
